%D9%81%D9%88%D9%84%D9%88%D8%B3%D8%AA%D8%B1%D8%A7%D9%86%D8%AACategory:FulvestrantFfwlfestrantFulvestrantFulvestrant%E3%83%95%E3%83%AB%E3%83%99%E3%82%B9%E3%83%88%E3%83%A9%E3%83%B3%E3%83%88%D0%A4%D0%BB%D1%83%D0%B2%D0%B5%D1%81%D1%82%D1%80%D0%B0%D0%BD%D1%82Fulwestrant%D0%A4%D1%83%D0%BB%D0%B2%D0%B5%D1%81%D1%82%D1%80%D0%B0%D0%BD%D1%82FulvestrantFulvestrant%D0%A4%D1%83%D0%BB%D1%8C%D0%B2%D0%B5%D1%81%D1%82%D1%80%D0%B0%D0%BD%D1%82FulvestrantQ5508491
about
P2176
P3781
Alisertib With or Without Fulvestrant in Treating Patients With Locally Advanced or Metastatic, Endocrine-Resistant Breast CancerPhase I Study of Combination of Gedatolisib With Palbociclib and Faslodex in Patients With ER+/HER2- Breast CancerROS1 Targeting With Crizotinib in Advanced E-cadherin Negative, ER Positive Lobular Breast Cancer or Diffuse Gastric Cancer StudyQuality Of Life While Receiving FaslodexSecond Line Breast Cancer TrialAZD2171 in Addition to Fulvestrant in Patients With Advanced Breast Cancer.Enzastaurin Plus Fulvestrant vs. Placebo Plus Fulvestrant in Breast CancerFulvestrant and Bevacizumab in Treating Patients With Metastatic Breast CancerEfficacy of Faslodex in Treatment of SLE Clinical, Serologic, and Molecular StudiesStudy Of CP-751,871 In Combination With Exemestane In Postmenopausal Women With Hormone Receptor Positive Advanced Breast CancerRetrospective Study Assessment Treatment Response Faslodex®( 500 mg)Faslodex Specific Clinical Experience Investigation1303GCC: Trastuzmab & Pertuzumab With Hormonal Therapy or Chemotherapy in Women Aged 60 and Over.Maintenance Hormone Therapy for Postmenopausal HR Positive Advanced Breast CancerFulvestrant +/- Akt Inhibition in Advanced Aromatase Inhibitor Resistant Breast CancerBevacizumab Plus Paclitaxel Optimization Study With Interventional Aintenance Endocrine Therapy in Breast CancerAnastrozole or Fulvestrant in Treating Postmenopausal Patients With Breast CancerFaslodex Post Marketing SurveillanceEvaluating Cancer Response to Treatment With Abemaciclib and Fulvestrant in Women With Recurrent Endometrial CancerThe Value of 18F-FES-PET/CT in Predicting Fulvestrant Efficacy in Breast CancerMEN1611 With Trastuzumab (+/- Fulvestrant) in Metastatic Breast Cancer500mg Fulvestrant in HR+ MBCRadiation Therapy, Palbociclib, and Hormone Therapy in Treating Breast Cancer Patients With Bone MetastasisOlaparib, Palbociclib and Fulvestrant in Patients With BRCA Mutation-associated, Hormone Receptor-positive, HER2-negative Metastatic Breast CancerTipifarnib and Fulvestrant in Hormone Receptor-Positive Metastatic Breast CancerA Study of SHR6390 in Combination With Letrozole or Anastrozole or Fulvestrant in Patients With HR Positive and HER2 Negative Advanced Breast CancerTreatment After Progression of Fulvestrant Among Metastatic Breast Cancer PatientsStudy to Determine the Utility of FES-PET in the Prediction of Response to Fulvestrant in Women With Estrogen Positive Metastatic Breast CancerFulvestrant, Palbociclib and Erdafitinib in ER+/HER2-/FGFR-amplified Metastatic Breast CancerStudy to Compare the Effects of AZD9496 vs Fulvestrant in Breast Cancer.Pre-operative Hormonal Treatment for Hormone Receptor Positive Breast CancerFaslodex Registry: Fulvestrant in Current Clinical PracticeFulvestrant With or Without Ganetespib in HR+ Breast CancerLung Cancer in Women Treated With Anti-oestrogens anD Inhibitors of EGFRCollection of Efficacy and Safety Data of Chinese Patients Who Have Received Faslodex 250mg TreatmentCabozantinib in Women With Metastatic Hormone-Receptor-Positive Breast CancerBKM120 and Fulvestrant for Treating Postmenopausal Patients With Estrogen Receptor-Positive Stage IV Breast CancerComparing the Efficacy and Tolerability of Fulvestrant 500 mg Versus 250 mg in Advanced Breast Cancer WomenA Dose Escalation Study Evaluating the Safety and Tolerability of GDC-0032 in Participants With Locally Advanced or Metastatic Solid Tumors or Non-Hodgkin's Lymphoma (NHL) and in Combination With Endocrine Therapy in Locally Advanced or MetastatStudy of AFP464 +/- Faslodex in ER + Breast Cancer
P4844
Emerging data on the efficacy and safety of fulvestrant, a unique antiestrogen therapy for advanced breast cancer.Fulvestrant for systemic therapy of locally advanced or metastatic breast cancer in postmenopausal women: a systematic review.Fulvestrant in the treatment of advanced breast cancer: a systematic review and meta-analysis of randomized controlled trials.Fulvestrant: a review of its use in the management of hormone receptor-positive metastatic breast cancer in postmenopausal women.Hepatic estrogen receptor α improves hepatosteatosis through upregulation of small heterodimer partner.
P921
description
chemical compound, synthetic estrogen receptor antagonist
@en
chemická sloučenina
@cs
chemische Verbindung
@de
chemische verbinding
@nl
component quimic
@oc
compost químic
@ca
composto chimico
@it
composto químico
@gl
composto químico
@pt
composto químico
@pt-br
name
Fulvestrant
@en
Fulvestrant
@es
Fulvestrant
@sh
Fulvestrant
@sr
Fulvestrant
@vi
Fulwestrant
@pl
ffwlfestrant
@cy
fulvestrant
@nn
Φουλβεστράντη
@el
Флувестрант
@mk
type
label
Fulvestrant
@en
Fulvestrant
@es
Fulvestrant
@sh
Fulvestrant
@sr
Fulvestrant
@vi
Fulwestrant
@pl
ffwlfestrant
@cy
fulvestrant
@nn
Φουλβεστράντη
@el
Флувестрант
@mk
altLabel
ICI 182,780
@cy
ICI 182,780
@en
SID29215034
@cy
SID29215034
@en
prefLabel
Fulvestrant
@en
Fulvestrant
@es
Fulvestrant
@sh
Fulvestrant
@sr
Fulvestrant
@vi
Fulwestrant
@pl
ffwlfestrant
@cy
fulvestrant
@nn
Φουλβεστράντη
@el
Флувестрант
@mk
P2868
P31
P4964
P486
P592
P6366
P661
P662
P683
P2017
C[C@]12CC[C@H]3[C@H]([C@@H]1CC ...... CCCCCCCS(=O)CCCC(C(F)(F)F)(F)F
P2067
P2115
N0000148770
P2175
P2275
fulvestrant
@en